SEC Form 4 · accession 0001140361-17-002344
Emergent BioSolutions Inc. · EBS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sue Bailey
Director
Period of report
Jan 17, 2017
Accepted (ET)
Jan 19, 2017 · 9:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001367644
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 1, 2016 | J | 152 | $0.00 | A | 34,637 | D | |
| Common StockF2 | Aug 1, 2016 | J | 604 | $0.00 | A | 35,241 | D | |
| Common StockF3 | Aug 1, 2016 | J | 577 | $0.00 | A | 35,818 | D | |
| Common StockF4 | Jan 17, 2017 | M | 3,157 | $10.64 | A | 38,975 | D | |
| Common StockF4,F5 | Jan 17, 2017 | S | 3,157 | $29.7789 | D | 35,818 | D | |
| Common StockF4 | Jan 17, 2017 | M | 3,157 | $14.71 | A | 38,975 | D | |
| Common StockF4,F5 | Jan 17, 2017 | S | 3,157 | $29.7789 | D | 35,818 | D | |
| Common StockF4 | Jan 17, 2017 | M | 3,157 | $20.08 | A | 38,975 | D | |
| Common StockF4,F5 | Jan 17, 2017 | S | 3,157 | $29.7789 | D | 35,818 | D | |
| Common StockF4 | Jan 17, 2017 | M | 4,735 | $13.37 | A | 40,553 | D | |
| Common StockF4,F5 | Jan 17, 2017 | S | 4,735 | $29.7789 | D | 35,818 | D | |
| Common StockF4 | Jan 17, 2017 | M | 3,157 | $13.00 | A | 38,975 | D | |
| Common StockF4,F5 | Jan 17, 2017 | S | 3,157 | $29.7789 | D | 35,818 | D | |
| Common StockF4 | Jan 17, 2017 | M | 2,061 | $18.64 | A | 37,879 | D | |
| Common StockF4 | Jan 17, 2017 | S | 2,061 | $29.7789 | D | 35,818 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F6,F8 | $10.64 | Aug 1, 2016 | J | 277 | A | — | May 20, 2019 | Common Stock | 277 | 3,157 | D |
| Stock Option (Right to buy)F7,F8 | $10.64 | Jan 17, 2017 | M | 3,157 | D | — | May 20, 2019 | Common Stock | 3,157 | 0 | D |
| Stock Option (Right to buy)F6,F8 | $14.71 | Aug 1, 2016 | J | 277 | A | — | May 19, 2020 | Common Stock | 277 | 3,157 | D |
| Stock Option (Right to buy)F7,F8 | $14.71 | Jan 17, 2017 | M | 3,157 | D | — | May 19, 2020 | Common Stock | 3,157 | 0 | D |
| Stock Option (Right to buy)F6,F8 | $20.08 | Aug 1, 2016 | J | 416 | A | — | May 18, 2021 | Common Stock | 416 | 4,736 | D |
| Stock Option (Right to buy)F7,F8 | $20.08 | Jan 17, 2017 | M | 3,157 | D | — | May 18, 2021 | Common Stock | 3,157 | 1,579 | D |
| Stock Option (Right to buy)F6,F8 | $13.37 | Aug 1, 2016 | J | 693 | A | — | May 16, 2019 | Common Stock | 693 | 7,893 | D |
| Stock Option (Right to buy)F7,F8 | $13.37 | Jan 17, 2017 | M | 4,735 | D | — | May 16, 2019 | Common Stock | 4,735 | 3,158 | D |
| Stock Option (Right to buy)F6,F8 | $13.00 | Aug 1, 2016 | J | 693 | A | — | May 22, 2020 | Common Stock | 693 | 7,893 | D |
| Stock Option (Right to buy)F7,F8 | $13.00 | Jan 17, 2017 | M | 3,157 | D | — | May 22, 2020 | Common Stock | 3,157 | 4,736 | D |
| Stock Option (Right to buy)F6,F8 | $18.64 | Aug 1, 2016 | J | 905 | A | — | May 21, 2021 | Common Stock | 905 | 10,305 | D |
| Stock Option (Right to buy)F7,F8 | $18.64 | Jan 17, 2017 | M | 2,061 | D | — | May 21, 2021 | Common Stock | 2,061 | 8,244 | D |
Explanation of responses
- F1In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017.
- F2In connection with the spin-off on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017 and May 2018.
- F3In connection with the spin-off the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017, May 2018 and May 2019.
- F4This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey.
- F5The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.68, inclusive.
- F6In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.
- F7Consists of an option granted under the company's stock incentive plan as amended and restated. The grant was made prior to the spin-off.
- F8The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.